Canbas Co., Ltd.
Records under this name other than the patents Canbas Co., Ltd. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 6 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,358,046 | Sensitivity test to predict efficacy of anti-cancer therapies Term ended Term ended Oct 19, 2025 · From the USPTO record | Term ended | Term ended Oct 19, 2025 | From the USPTO record |
| US 7,407,985 | Compounds that abrogate DNA damage induced cell cycle G2 checkpoint and/or augment anti-cancer activity of DNA-damaging treatments Term ended Term ended Mar 12, 2024 · From the USPTO record | Term ended | Term ended Mar 12, 2024 | From the USPTO record |
| US 7,476,657 | Peptides and Peptidomimetics Having Anti-Proliferative Activity And/Or That Augment Nucleic Acid Damaging Agents or Treatments Term ended Term ended Sep 25, 2023 · High confidence | Term ended | Term ended Sep 25, 2023 | High confidence |
| US 7,851,592 | Compositions and methods for inhibiting G2 cell cycle arrest and sensitizing cells to DNA damaging agents Term ended Term ended Aug 12, 2023 · From the USPTO record | Term ended | Term ended Aug 12, 2023 | From the USPTO record |
| US 6,995,135 | Peptides and Peptidomimetics Having Anti-Proliferative Activity And/Or That Augment Nucleic Acid Damaging Agents or Treatments Term ended Term ended Jan 17, 2023 · High confidence | Term ended | Term ended Jan 17, 2023 | High confidence |
| US 7,125,842 | Anti-Fungal Compounds and Methods of Use Term ended Term ended Jan 17, 2023 · High confidence | Term ended | Term ended Jan 17, 2023 | High confidence |
| US 7,479,484 | Peptides and Peptidomimetics Having Immune-Modulating, Anti-Inflammatory, and Anti-Viral Activity Term ended Term ended Jan 17, 2023 · High confidence | Term ended | Term ended Jan 17, 2023 | High confidence |
| US 6,881,575 | Compositions and methods for inhibiting G2 cell cycle arrest and sensitizing cells to DNA damaging agents Term ended Term ended Aug 2, 2021 · From the USPTO record | Term ended | Term ended Aug 2, 2021 | From the USPTO record |
| US 7,030,111 | Compounds that abrogate DNA-damage-induced cell cycle G2 checkpoint and/or augment the anti-cancer activity of DNA damaging treatments Lapsed on the fee record Ended Apr 18, 2018 · From the USPTO record | Lapsed on the fee record | Ended Apr 18, 2018 | From the USPTO record |
| US 7,652,042 | Compounds that abrogate DNA damage induced cell cycle G2 checkpoint and/or augment anti-cancer activity of DNA-damaging treatments Lapsed on the fee record Ended Jan 26, 2018 · From the USPTO record | Lapsed on the fee record | Ended Jan 26, 2018 | From the USPTO record |